Adobe, Analogic, Oracle, Orexigen, Vivus : U.S. Equity Preview

Sept. 21 (Bloomberg) -- Shares of the following companies may have unusual moves in U.S. trading. Stock symbols are in parentheses.

Adobe Systems Inc. (ADBE US): The world’s largest maker of graphic-design software forecast fourth-quarter revenue of at least $1.08 billion, exceeding analysts’ estimates of $1.07 billion on average, citing demand from business customers.

Analogic Corp. (ALOG US): The medical and airport-security device maker reported fourth-quarter earnings of 83 cents a share, beating the 62 cent average estimate of two analysts.

Oracle Corp. (ORCL US): The Redwood City, California-based supplier reported a first-quarter profit of 48 cents, topping analysts’ estimates by 1 cent, as companies increased spending on database software and applications that help run their businesses.

Orexigen Therapeutics Inc. (OREX US): The drugmaker, which is one of three companies with rival obesity treatments competing for approval, is renewing development of the experiment obesity drug Contrave after reaching an agreement with U.S. regulators to further study heart risks.

Vivus Inc. (VVUS) has also been vying to introduce the first new obesity medicine in the U.S.

PharMerica Corp. (PMC US): The provider of pharmacy services based said its board unanimously voted to reject a hostile bid by Omnicare Inc. to acquire the Louisville, Kentucky-based company for $15 a share.

Realty Income Corp. (O US): The real estate investment trust that acquires retail locations started a public offering of 6 million shares. Proceeds will be used to pay debt.

To contact the reporter on this story: Inyoung Hwang in New York at

To contact the editor responsible for this story: Nick Baker at